NCT05876754 2026-02-19
ProvIDHe
Servier
Phase 3 Recruiting
Clinical Trials
10 trialsNCT07006688 2026-02-18
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Servier
Phase 1 Recruiting
NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT03173248 2025-11-10
AGILE
Servier
Phase 3 Active not recruiting
NCT02074839 2025-06-08
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
Phase 1 Recruiting
NCT02632708 2025-04-11
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Active not recruiting
NCT05907057 2025-04-11
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier
Phase 3 Recruiting
NCT02989857 2024-08-20
ClarIDHy
Servier
Phase 3 Completed
NCT04176393 2023-02-13
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
CStone Pharmaceuticals
Phase 1 Completed